Evotec (EVO) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.07

Estimate

-$0.31

Surprise

+76.2%

Score today

4.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Evotec (EVO) reported a narrower loss than forecast — adjusted EPS of -$0.07 against the -$0.31 estimate (a 76.2% beat on a still-unprofitable quarter).

• HC Wainwright & Co. Maintains Buy on Evotec, Raises Price Target to $5 — benzinga, 2026-11-06
• Vertex Pharmaceuticals Selects Evotec's J.POD Facility for Commercial Production — fiscal.ai, 2026-11-05
• JPMorgan Chase Files Voting Rights Notification for Evotec SE — fiscal.ai, 2026-11-05

TrendMatrix currently rates EVO Sell at 4.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +76.2% surprise compares with a -18.9% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$1.70

Price target

$3.59

Stop

$1.58

Upside to target

+111.2%

Reward-to-risk

7.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$630.8M

P/E (fwd)

-9.3

52-week range

$1.33–$3.87

Off 52-week high

56.1%

RSI (14)

69

Volume vs avg

0.53×

Score today

4.4/10